OBJECTIVE:To evaluate and compare the efficacy and safety of telmisartan and amlodipine tablets ( compound preparation) versus amlodipine alone in treatment of hypertension.METHODS:80 patients with essential hypertension were randomly divided into two groups of 40 cases each with random number table method.Both groups were given amlodipine 5 mg for 6 consecutive weeks, the compound preparation group was given telmisartan 80 mg plus amlodipine 5 mg while the single drug group was given single amlodipine 5 mg alone.The blood pressure ( BP ) of patients was measured and the incidence of adverse drug reactions were recorded at 4 and 8 weeks of treatment. RESULTS:The BP in the compound agent group at 4 and 8 weeks showed greater decrease than in single drug group, and rate of patients whose BP met the target value was also higher than in the single drug group, showing statistically significant differences between the two groups( P0.05 ) , and serious adverse reactions were noted in none of the two groups.CONCLUSIONS: With lower cost and a good safety, telmisartan and amlodipine compound preparation can effectively reduce BP and prompt BP to meet normal target meanwhile improving the symptoms of left ventricular hypertrophy in patients with hypertension, which thus is worthy of clinical application.%目的：比较替米沙坦联合氨氯地平与氨氯地平单药治疗原发性高血压病的疗效及安全性。方法：选择80例原发性高血压病患者，均给予氨氯地平5 mg，连续治疗6周，然后按照随机数字表法分为联合用药组和单药组各40例。联合用药组患者给予替米沙坦80 mg与氨氯地平5 mg联合治疗，单药组患者仅给予氨氯地平5 mg单药治疗，分别于治疗4周及8周后测量患者血压，并记录不良反应发生情况。结果：联合用药组患者治疗4周及8周后血压下降程度均高于单药组，且血压达标率也高于单药组，差异具有统计学意义（ P＜0.05）；联合用药组动态血压监测变化较单药组明显改善，其血压构型达标有效率为90.0％，明显高于单药组的60.0％，差异具有统计学意义（P＜0.05）；联合用药组左心肥厚指标左心室后壁厚度（LVPWT）、舒张末期室间隔厚度（LVSTD）、心室重量（LVM）及左心室重量指数（LVMI）改善程度明显优于单药组，差异具有统计学意义（P＜0.05）；联合用药组的成本-效果分析中，ΔC／ΔE值仅为0.91，可作为较为合理的原发性高血压治疗方案。另外，联合用药组患者不良反应发生率为10.0％，与单药组的7.5％比较，差异无统计学意义（P＞0.05），2组患者均无严重不良反应发生。结论：替米沙坦联合氨氯地平治疗原发性高血压病，可有效降低血压，促使血压达到正常目标，同时改善患者左心肥厚症状，费用较低且安全性高，值得临床推广应用。
展开▼
